IDEAYA Enters Collaboration With Roche To Evaluate The Efficacy And Safety Of IDE892, Its Investigational PRMT5 Inhibitor, With Roche's RG6505

IDEAYA Biosciences
ROCHE HOLDINGS AG

IDEAYA Biosciences

IDYA

0.00

ROCHE HOLDINGS AG

RHHBY

0.00
  • IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma
  • IDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the study
  • MTAP-deletion is estimated to occur in up to 40% of PDAC
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.